[1]
|
Díaz, L.A., Fuentes-López, E., Ayares, G., Idalsoaga, F., Arnold, J., Márquez-Lomas, A., et al. (2022) The Establishment of Public Health Policies and the Burden of Non-Alcoholic Fatty Liver Disease in the Americas. The Lancet Gastroenterology & Hepatology, 7, 552-559. https://doi.org/10.1016/s2468-1253(22)00008-5
|
[2]
|
Younossi, Z.M., Koenig, A.B., Abdelatif, D., Fazel, Y., Henry, L. and Wymer, M. (2016) Global Epidemiology of Nonalcoholic Fatty Liver Disease—Meta-Analytic Assessment of Prevalence, Incidence, and Outcomes. Hepatology, 64, 73-84. https://doi.org/10.1002/hep.28431
|
[3]
|
Le, M.H., Yeo, Y.H., Li, X., Li, J., Zou, B., Wu, Y., et al. (2022) 2019 Global NAFLD Prevalence: A Systematic Review and Meta-Analysis. Clinical Gastroenterology and Hepatology, 20, 2809-2817.e28. https://doi.org/10.1016/j.cgh.2021.12.002
|
[4]
|
Byrne, C.D. and Targher, G. (2015) NAFLD: A Multisystem Disease. Journal of Hepatology, 62, S47-S64. https://doi.org/10.1016/j.jhep.2014.12.012
|
[5]
|
Younossi, Z.M., Golabi, P., de Avila, L., Paik, J.M., Srishord, M., Fukui, N., et al. (2019) The Global Epidemiology of NAFLD and NASH in Patients with Type 2 Diabetes: A Systematic Review and Meta-Analysis. Journal of Hepatology, 71, 793-801. https://doi.org/10.1016/j.jhep.2019.06.021
|
[6]
|
Hossain, N., Afendy, A., Stepanova, M., Nader, F., Srishord, M., Rafiq, N., et al. (2009) Independent Predictors of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 7, 1224-1229.e2. https://doi.org/10.1016/j.cgh.2009.06.007
|
[7]
|
Fracanzani, A.L., Valenti, L., Bugianesi, E., Andreoletti, M., Colli, A., Vanni, E., et al. (2008) Risk of Severe Liver Disease in Nonalcoholic Fatty Liver Disease with Normal Aminotransferase Levels: A Role for Insulin Resistance and Diabetes. Hepatology, 48, 792-798. https://doi.org/10.1002/hep.22429
|
[8]
|
Ajmera, V., Cepin, S., Tesfai, K., Hofflich, H., Cadman, K., Lopez, S., et al. (2023) A Prospective Study on the Prevalence of NAFLD, Advanced Fibrosis, Cirrhosis and Hepatocellular Carcinoma in People with Type 2 Diabetes. Journal of Hepatology, 78, 471-478. https://doi.org/10.1016/j.jhep.2022.11.010
|
[9]
|
Dobiás̆ová, M. and Frohlich, J. (2001) The Plasma Parameter Log (TG/HDL-C) as an Atherogenic Index: Correlation with Lipoprotein Particle Size and Esterification Rate Inapob-Lipoprotein-Depleted Plasma (ferhdl). Clinical Biochemistry, 34, 583-588. https://doi.org/10.1016/s0009-9120(01)00263-6
|
[10]
|
Wang, Q., Zheng, D., Liu, J., Fang, L. and Li, Q. (2018) Atherogenic Index of Plasma Is a Novel Predictor of Non-Alcoholic Fatty Liver Disease in Obese Participants: A Cross-Sectional Study. Lipids in Health and Disease, 17, Article No. 284. https://doi.org/10.1186/s12944-018-0932-0
|
[11]
|
Liu, J., Zhou, L., An, Y., Wang, Y. and Wang, G. (2022) The Atherogenic Index of Plasma: A Novel Factor More Closely Related to Non-Alcoholic Fatty Liver Disease than Other Lipid Parameters in Adults. Frontiers in Nutrition, 9, Article ID: 954219. https://doi.org/10.3389/fnut.2022.954219
|
[12]
|
Tsochatzis, E.A., Gurusamy, K.S., Ntaoula, S., Cholongitas, E., Davidson, B.R. and Burroughs, A.K. (2011) Elastography for the Diagnosis of Severity of Fibrosis in Chronic Liver Disease: A Meta-Analysis of Diagnostic Accuracy. Journal of Hepatology, 54, 650-659. https://doi.org/10.1016/j.jhep.2010.07.033
|
[13]
|
Tang, A., Cloutier, G., Szeverenyi, N.M. and Sirlin, C.B. (2015) Ultrasound Elastography and MR Elastography for Assessing Liver Fibrosis: Part 1, Principles and Techniques. American Journal of Roentgenology, 205, 22-32. https://doi.org/10.2214/ajr.15.14552
|
[14]
|
Castéra, L., Vergniol, J., Foucher, J., Le Bail, B., Chanteloup, E., Haaser, M., et al. (2005) Prospective Comparison of Transient Elastography, Fibrotest, APRI, and Liver Biopsy for the Assessment of Fibrosis in Chronic Hepatitis C. Gastroenterology, 128, 343-350. https://doi.org/10.1053/j.gastro.2004.11.018
|
[15]
|
Eddowes, P.J., Sasso, M., Allison, M., Tsochatzis, E., Anstee, Q.M., Sheridan, D., et al. (2019) Accuracy of Fibroscan Controlled Attenuation Parameter and Liver Stiffness Measurement in Assessing Steatosis and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Gastroenterology, 156, 1717-1730. https://doi.org/10.1053/j.gastro.2019.01.042
|
[16]
|
Man, S., Lv, J., Yu, C., Deng, Y., Yin, J., Wang, B., et al. (2022) Association between Metabolically Healthy Obesity and Non-Alcoholic Fatty Liver Disease. Hepatology International, 16, 1412-1423. https://doi.org/10.1007/s12072-022-10395-8
|
[17]
|
Xue, Y., Xu, J., Li, M. and Gao, Y. (2022) Potential Screening Indicators for Early Diagnosis of NAFLD/MAFLD and Liver Fibrosis: Triglyceride Glucose Index-related Parameters. Frontiers in Endocrinology, 13, Article ID: 951689. https://doi.org/10.3389/fendo.2022.951689
|
[18]
|
Peng, H., Pan, L., Ran, S., Wang, M., Huang, S., Zhao, M., et al. (2023) Prediction of MAFLD and NAFLD Using Different Screening Indexes: A Cross-Sectional Study in U.S. Adults. Frontiers in Endocrinology, 14, Article ID: 1083032. https://doi.org/10.3389/fendo.2023.1083032
|
[19]
|
Shen, Y., Wu, Y., Fu, M., Zhu, K. and Wang, J. (2023) Association between Weight-Adjusted-Waist Index with Hepatic Steatosis and Liver Fibrosis: A Nationally Representative Cross-Sectional Study from NHANES 2017 to 2020. Frontiers in Endocrinology, 14, Article ID: 1159055. https://doi.org/10.3389/fendo.2023.1159055
|
[20]
|
Buzzetti, E., Pinzani, M. and Tsochatzis, E.A. (2016) The Multiple-Hit Pathogenesis of Non-Alcoholic Fatty Liver Disease (nafld). Metabolism, 65, 1038-1048. https://doi.org/10.1016/j.metabol.2015.12.012
|
[21]
|
Sanyal, A.J., Campbell-Sargent, C., Mirshahi, F., Rizzo, W.B., Contos, M.J., Sterling, R.K., et al. (2001) Nonalcoholic Steatohepatitis: Association of Insulin Resistance and Mitochondrial Abnormalities. Gastroenterology, 120, 1183-1192. https://doi.org/10.1053/gast.2001.23256
|
[22]
|
George, D.K., Goldwurm, S., Macdonald, G.A., Cowley, L.L., Walker, N.I., Ward, P.J., et al. (1998) Increased Hepatic Iron Concentration in Nonalcoholic Steatohepatitis Is Associated with Increased Fibrosis. Gastroenterology, 114, 311-318. https://doi.org/10.1016/s0016-5085(98)70482-2
|
[23]
|
Valenti, L., Fracanzani, A.L., Bugianesi, E., Dongiovanni, P., Galmozzi, E., Vanni, E., et al. (2010) HFE Genotype, Parenchymal Iron Accumulation, and Liver Fibrosis in Patients with Nonalcoholic Fatty Liver Disease. Gastroenterology, 138, 905-912. https://doi.org/10.1053/j.gastro.2009.11.013
|
[24]
|
Strauss, R.S., Barlow, S.E. and Dietz, W.H. (2000) Prevalence of Abnormal Serum Aminotransferase Values in Overweight and Obese Adolescents. Journal of Pediatrics, 136, 0727-0733. https://doi.org/10.1067/mpd.2000.102940
|
[25]
|
Sastre, J., Pallardó, F.V., Llopis, J., Furukawa, T., Vinã, J.R. and Viña, J. (1989) Glutathione Depletion by Hyperphagia-Induced Obesity. Life Sciences, 45, 183-187. https://doi.org/10.1016/0024-3205(89)90293-2
|
[26]
|
Lavine, J.E. (2000) Vitamin E Treatment of Nonalcoholic Steatohepatitis in Children: A Pilot Study. The Journal of Pediatrics, 136, 734-738. https://doi.org/10.1016/s0022-3476(00)05040-x
|
[27]
|
Zhao, M., Zhao, L., Xiong, X., He, Y., Huang, W., Liu, Z., et al. (2020) TMAVA, a Metabolite of Intestinal Microbes, Is Increased in Plasma from Patients with Liver Steatosis, Inhibits Γ-Butyrobetaine Hydroxylase, and Exacerbates Fatty Liver in Mice. Gastroenterology, 158, 2266-2281.e27. https://doi.org/10.1053/j.gastro.2020.02.033
|
[28]
|
Begriche, K., Igoudjil, A., Pessayre, D. and Fromenty, B. (2006) Mitochondrial Dysfunction in NASH: Causes, Consequences and Possible Means to Prevent It. Mitochondrion, 6, 1-28. https://doi.org/10.1016/j.mito.2005.10.004
|
[29]
|
Katsiki, N., Mikhailidis, D.P. and Mantzoros, C.S. (2016) Non-Alcoholic Fatty Liver Disease and Dyslipidemia: An Update. Metabolism, 65, 1109-1123. https://doi.org/10.1016/j.metabol.2016.05.003
|
[30]
|
Yin, B., Wu, Z., Xia, Y., Xiao, S., Chen, L. and Li, Y. (2023) Non-Linear Association of Atherogenic Index of Plasma with Insulin Resistance and Type 2 Diabetes: A Cross-Sectional Study. Cardiovascular Diabetology, 22, 157. https://doi.org/10.1186/s12933-023-01886-5
|
[31]
|
Cusi, K. (2020) Time to Include Nonalcoholic Steatohepatitis in the Management of Patients with Type 2 Diabetes. Diabetes Care, 43, 275-279. https://doi.org/10.2337/dci19-0064
|
[32]
|
Noureddin, M., Jones, C., Alkhouri, N., Gomez, E.V., Dieterich, D.T., Rinella, M.E., et al. (2020) Screening for Nonalcoholic Fatty Liver Disease in Persons with Type 2 Diabetes in the United States Is Cost-Effective: A Comprehensive Cost-Utility Analysis. Gastroenterology, 159, 1985-1987.e4. https://doi.org/10.1053/j.gastro.2020.07.050
|
[33]
|
Weston, S.R., Leyden, W., Murphy, R., Bass, N.M., Bell, B.P., Manos, M.M., et al. (2005) Racial and Ethnic Distribution of Nonalcoholic Fatty Liver in Persons with Newly Diagnosed Chronic Liver Disease. Hepatology, 41, 372-379. https://doi.org/10.1002/hep.20554
|
[34]
|
Browning, J.D., Szczepaniak, L.S., Dobbins, R., Nuremberg, P., Horton, J.D., Cohen, J.C., et al. (2004) Prevalence of Hepatic Steatosis in an Urban Population in the United States: Impact of Ethnicity. Hepatology, 40, 1387-1395. https://doi.org/10.1002/hep.20466
|
[35]
|
Williams, C.D., Stengel, J., Asike, M.I., Torres, D.M., Shaw, J., Contreras, M., et al. (2011) Prevalence of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis among a Largely Middle-Aged Population Utilizing Ultrasound and Liver Biopsy: A Prospective Study. Gastroenterology, 140, 124-131. https://doi.org/10.1053/j.gastro.2010.09.038
|